Literature DB >> 19815836

Species-specific anticoagulant and mitogenic activities of murine protein S.

José A Fernández1, Mary J Heeb, Xiao Xu, Itender Singh, Berislav V Zlokovic, John H Griffin.   

Abstract

BACKGROUND: The protein C pathway down-regulates thrombin generation and promotes cytoprotection during inflammation and stress. In preclinical studies using models of murine injury (e.g., sepsis and ischemic stroke), murine protein S may be required because of restrictive species specificity. DESIGN AND METHODS: We prepared and characterized recombinant murine protein S using novel coagulation assays, immunoassays, and cell proliferation assays.
RESULTS: Purified murine protein S had good anticoagulant co-factor activity for murine activated protein C, but not for human activated protein C, in mouse or rat plasma. In human plasma, murine protein S was a poor co-factor for murine activated protein C and had no anticoagulant effect with human activated protein C, suggesting protein S species specificity for factor V in addition to activated protein C. We estimated that mouse plasma contains 22+/-1 microg/mL protein S and developed assays to measure activated protein C co-factor activity of the protein S in murine plasma. Activated protein C-independent anticoagulant activity of murine protein S was demonstrable and quantifiable in mouse plasma, and this activity was enhanced by exogenous murine protein S. Murine protein S promoted the proliferation of mouse and human smooth muscle cells. The potency of murine protein S was higher for mouse cells than for human cells and similarly, human protein S was more potent for human cells than for mouse cells.
CONCLUSIONS: The spectrum of bioactivities of recombinant murine protein S with mouse plasma and smooth muscle cells is similar to that of human protein S. However, in vitro and in vivo studies of the protein C pathway in murine disease models are more appropriately performed using murine protein S. This study extends previous observations regarding the remarkable species specificity of protein S to the mouse.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19815836      PMCID: PMC2791928          DOI: 10.3324/haematol.2009.009233

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  55 in total

Review 1.  Cellular effects and signalling pathways activated by the anti-coagulant factor, protein S, in vascular cells protein S cellular effects.

Authors:  C Kanthou; O Benzakour
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

2.  Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells.

Authors:  Howard A Anderson; Caroline A Maylock; Joy A Williams; Cloud P Paweletz; Hongjun Shu; Emily Shacter
Journal:  Nat Immunol       Date:  2002-11-25       Impact factor: 25.606

3.  Protein S down-regulates factor Xase activity independent of activated protein C: specific binding of factor VIII(a) to protein S inhibits interactions with factor IXa.

Authors:  Masahiro Takeyama; Keiji Nogami; Evgueni L Saenko; Tetsuhiro Soeda; Katsumi Nishiya; Kenichi Ogiwara; Akira Yoshioka; Midori Shima
Journal:  Br J Haematol       Date:  2008-08-28       Impact factor: 6.998

4.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

5.  Expression and characterization of recombinant murine factor VIII.

Authors:  Christopher Doering; Ernest T Parker; John F Healey; Heather N Craddock; Rachel T Barrow; Pete Lollar
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

6.  Molecular cloning and functional characterization of rat plasma protein S.

Authors:  F Yasuda; T Hayashi; K Tanitame; J Nishioka; K Suzuki
Journal:  J Biochem       Date:  1995-02       Impact factor: 3.387

7.  Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant.

Authors:  Laurent O Mosnier; Antonella Zampolli; Edward J Kerschen; Reto A Schuepbach; Yajnavalka Banerjee; José A Fernández; Xia V Yang; Matthias Riewald; Hartmut Weiler; Zaverio M Ruggeri; John H Griffin
Journal:  Blood       Date:  2009-02-24       Impact factor: 22.113

Review 8.  Animal models of focal and global cerebral ischemia.

Authors:  Richard J Traystman
Journal:  ILAR J       Date:  2003

9.  Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Analysis of the binding characteristics and mitogenic properties of protein S on human vascular smooth muscle cells.

Authors:  O Benzakour; C Formstone; S Rahman; C Kanthou; U Dennehy; M F Scully; V V Kakkar; D N Cooper
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

10.  Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells.

Authors:  Joanna H Webb; Anna M Blom; Björn Dahlbäck
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

View more
  15 in total

1.  Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor.

Authors:  Donghui Zhu; Yaoming Wang; Itender Singh; Robert D Bell; Rashid Deane; Zhihui Zhong; Abhay Sagare; Ethan A Winkler; Berislav V Zlokovic
Journal:  Blood       Date:  2010-03-26       Impact factor: 22.113

Review 2.  TAM receptor signaling in immune homeostasis.

Authors:  Carla V Rothlin; Eugenio A Carrera-Silva; Lidia Bosurgi; Sourav Ghosh
Journal:  Annu Rev Immunol       Date:  2015-01-14       Impact factor: 28.527

3.  Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model.

Authors:  M J Heeb; U Marzec; A Gruber; S R Hanson
Journal:  Thromb Haemost       Date:  2012-02-28       Impact factor: 5.249

4.  Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.

Authors:  Sara Calzavarini; Raja Prince-Eladnani; François Saller; Luca Bologna; Laurent Burnier; Anne C Brisset; Claudia Quarroz; Maria Desiré Reina Caro; Vladimir Ermolayev; Yasuhiro Matsumura; José A Fernández; Tilman M Hackeng; John H Griffin; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2020-05-28       Impact factor: 22.113

5.  Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region.

Authors:  Zhihui Zhong; Yaoming Wang; Huang Guo; Abhay Sagare; José A Fernández; Robert D Bell; Theresa M Barrett; John H Griffin; Robert S Freeman; Berislav V Zlokovic
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

6.  Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation.

Authors:  Fumiaki Banno; Toshiyuki Kita; José A Fernández; Hiroji Yanamoto; Yuko Tashima; Koichi Kokame; John H Griffin; Toshiyuki Miyata
Journal:  Blood       Date:  2015-08-06       Impact factor: 22.113

7.  Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation.

Authors:  Mary J Heeb; Rolf M Mesters; José A Fernández; Tilman M Hackeng; Ryon K Nakasone; John H Griffin
Journal:  Thromb Haemost       Date:  2013-05-23       Impact factor: 5.249

8.  Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis.

Authors:  Tal Burstyn-Cohen; Mary Jo Heeb; Greg Lemke
Journal:  J Clin Invest       Date:  2009-10       Impact factor: 14.808

9.  Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway.

Authors:  Huang Guo; Theresa M Barrett; Zhihui Zhong; José A Fernández; John H Griffin; Robert S Freeman; Berislav V Zlokovic
Journal:  Mol Neurodegener       Date:  2011-02-03       Impact factor: 14.195

10.  An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.

Authors:  Annette von Drygalski; Vikas Bhat; Andrew J Gale; Laurent Burnier; Thomas J Cramer; John H Griffin; Laurent O Mosnier
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.